Luis Felipe C. Ensina, AAAAI 2023: Treatment options and unmet needs in chronic spontaneous urticaria
Chronic spontaneous urticaria (CSU) is a skin condition defined by the spontaneous presence of hives for prolonged periods of time and angioedema. There is no known cause however CSU has been linked to the immune system and autoimmune conditions. touchIMMUNOLOGY were delighted to speak with Dr. Luis Felipe C. Ensina (Federal University of São Paulo, São Paulo, Brazil) around the current options and unmet needs in the treatment of CSU and the burden this condition has on patients.
The abstract ‘Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: Results from the Phase-3 Pivotal Trials.‘ (Abstract number: 402) was presented at AAAAI 2023, February 24–27, 2023, #AAAAI2023.
- What are the current options and unmet needs in the treatment of chronic spontaneous urticaria? (0:24)
- What is the burden of chronic spontaneous urticaria on patients? (1:52)
Disclosures: Luis Felipe C. Ensina discloses consulting for Novartis; serving on advisory boards for Abbvie, Novartis and Sanofi; receiving honoraria from Abbvie, Novartis and Sanofi; and participating in Speaker’s Bureaus for Abbvie, Novartis, and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the American Academy of Allergy Asthma & Immunology Annual Meeting 2023.
Click here for more content from Luis Felipe C. Ensina.
What are the current options and unmet needs in the treatment of chronic spontaneous urticaria? (0:24)
Well, regarding the current treatment for chronic spontaneous urticaria (CSU). According to the current guidelines, we have three steps of treatment. The first one, second generation antihistamines in standard or up to fourfold doses for those patients who are refractory to antihistamines, which is around 50% to 60%. The guideline recommends omalizumab and then IgG antibody, which is effective in up to 80-85% of patients with a very safe profile. For those who are refractory to omalizumab or can’t use it for any reason, the recommendation is to use cyclosporine. Cyclosporine is fine but has some potential side effects that we must, we must watch. The main unmet need, in my opinion, is for the patients who are refractory for omalizumab and should use cyclosporine, because of the side effects of cyclosporine it would be very nice to have another option than cyclosporine for those who are refractory to omalizumab.
What is the burden of chronic spontaneous urticaria on patients? (1:52)
The main issue for patients with CSU is the huge impact that it has in patients’ quality of life. So, imagine being bitten by hundreds of mosquitos all the time. That’s the sensation that a patient with CSU has. So, the itching, the aspect of the lesions, then angioedema, the swelling, they effect a lot in social life, in concentration. So, it’s hard for the patients to concentrate, to study or to work. So, their quality of life is miserable.
Subtitles and transcript are autogenerated.
Share this Video
Related Videos In Allergic Conditions
William R. Lumry, AAAAI 2023: Lanadelumab for paediatric patients aged 2 to <12 years with hereditary angioedema – the SPRING Study
The SPRING Study (NCT04070326) was a phase 3 study that investigated the safety, pharmacokinetics, and pharmacodynamics of lanadelumab for prevention of hereditary angioedema (HAE) attacks in children. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the aims, design and findings from the SPRING Study and how […]
William R. Lumry, AAAAI 2023: Current treatment paradigm and unmet needs in hereditary angioedema
Hereditary angioedema (HAE) is a rare genetic disease that reduces C1 inhibitor levels and impacts the regulation of several pathways involved in dilation of the blood vessels and results in recurrent episodes of severe swelling. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the unmet needs […]
Ralph Mösges, AAAAI 2023: Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergy
Mannan conjugated birch pollen allergoids are an immunotherapy currently under clinical investigation for the treatment of birch pollen allergy. touchIMMUNOLOGY caught up with Prof. Ralph Mösges (University of Cologne, Cologne, Germany) to discuss the rationale and methodology of the the clinical trial programme for Mannan conjugated birch pollen allergoids, the efficacy and safety findings so […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!